Shopping Cart 0
Cart Subtotal
AED 0

Janssen Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Janssen Pharmaceuticals Inc (Janssen), a subsidiary of Johnson & Johnson is a pharmaceutical company that develops drugs. The company offers medicines for an array of health conditions in therapeutic areas of attention deficit hyperactivity disorder, general medicine, mental health, neurologics, pain management, women's health, and others. It also offers treatments for acid reflux disease, infectious diseases, bipolar I disorder, schizophrenia, alzheimer's disease, epilepsy, migraine prevention and treatment. The company sells its products through a network of distributors across the US. It caters services to cardiovascular & metabolism, immunology, infectious diseases, vaccines, neuroscience,Oncology and other therapeutic areas. Janssen is headquartered in Titusville, New Jersey, the US.

Janssen Pharmaceuticals Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Janssen Pharma Acquires CERC-501 from Cerecor 17

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18

Venture Financing 19

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 19

Partnerships 20

Janssen Pharma Enters into Research and Option Agreement with Arrowhead Pharma 20

MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 21

GenomeDx Biosciences Enters into Agreement with Janssen Pharma 22

Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 23

Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 24

Janssen Pharma Enters into Research Partnership with Beacon Discovery 25

Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 26

Genomic Health Enters into Research Agreement with Janssen Pharma 27

Cerveau Technologies Enters into Agreement with Janssen Pharma 28

University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 29

PeptiDream Enters into Agreement with Janssen Pharma 30

Janssen Pharma Enters into Partnership with Premier 31

Renova Therapeutics Enters into Agreement with Janssen Pharma 32

Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 33

Karolinska Institutet Partners with Johnson & Johnson Companies 34

Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 35

Janssen Pharma Enters into Partnership with Bird Rock Bio 36

DiamiR Enters into Research Agreement with Janssen Pharma 37

Janssen Pharma Enters into Agreement with University of Pennsylvania 38

Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 39

Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 40

Janssen Pharma Enters into Agreement with University of California, San Diego 41

Cypralis Enters into Research Agreement with Janssen Pharma 42

BlinkBio Enters into Discovery Agreement with Janssen Pharma 43

NeurOp Enters into Research Agreement with Janssen Pharma 44

AC Immune Enters into Research Agreement with Janssen Pharma 45

Alector Enters Into Research Agreement With Janssen Pharma 46

DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 47

Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 48

Mellitech Enters into Agreement with Janssen Pharma 50

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 51

Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 52

Licensing Agreements 53

Janssen Pharma Enters into Licensing Agreement with Arrowhead Pharma 53

Janssen Pharma Enters into Licensing Agreement with St Vincent's Institute of Medical Research 54

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 55

Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 56

Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 57

Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 58

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 59

Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 60

Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 61

Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 62

AC Immune Enters into Licensing Agreement with Janssen Pharma 63

Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 64

Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 66

Janssen Pharma Enters into Licensing Agreement with BiocerOX 67

Orion Enters Into Licensing Agreement With Janssen Pharma 68

Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 69

GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 70

NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 71

Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 72

Shionogi Enters Into Licensing Agreement With Janssen Pharma 74

Depomed Enters Into Licensing Agreement With Janssen Pharma 75

Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 76

Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 77

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 78

Asset Transactions 80

VIVUS Acquires Assets from Janssen Pharma for USD135 Million 80

Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 81

Vivus Acquires Topiramate Related Patents from Janssen Pharma 83

Acquisition 84

Janssen Pharma Acquires XO1 84

Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 85

Janssen Pharmaceuticals Inc-Key Competitors 87

Janssen Pharmaceuticals Inc-Key Employees 88

Janssen Pharmaceuticals Inc-Locations And Subsidiaries 89

Head Office 89

Other Locations & Subsidiaries 89

Recent Developments 90

Strategy And Business Planning 90

Oct 05, 2018: Janssen signs USD 3.7bn worth licence agreements with Arrowhead 90

Legal and Regulatory 91

May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 91

Government and Public Interest 92

Feb 21, 2018: New Real-World Analysis Published in The Journal of Clinical Psychiatry Illuminates the Significant Economic Toll of Treatment-Resistant Depression on Individuals, Employers and Payers 92

Nov 30, 2017: New HIV Prevention Trials Hold Promise for New Prevention Options for Women 93

Sep 26, 2017: Janssen Announces HealtheVoices Impact Fund Recipients 94

Other Significant Developments 95

Oct 09, 2017: Johnson & Johnson investing USD 350M in EU biologics operation, adding 200 jobs 95

Appendix 96

Methodology 96

About GlobalData 96

Contact Us 96

Disclaimer 96


List Of Figure

List of Figures

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Janssen Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Janssen Pharma Acquires CERC-501 from Cerecor 17

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 19

Janssen Pharma Enters into Research and Option Agreement with Arrowhead Pharma 20

MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 21

GenomeDx Biosciences Enters into Agreement with Janssen Pharma 22

Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 23

Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 24

Janssen Pharma Enters into Research Partnership with Beacon Discovery 25

Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 26

Genomic Health Enters into Research Agreement with Janssen Pharma 27

Cerveau Technologies Enters into Agreement with Janssen Pharma 28

University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 29

PeptiDream Enters into Agreement with Janssen Pharma 30

Janssen Pharma Enters into Partnership with Premier 31

Renova Therapeutics Enters into Agreement with Janssen Pharma 32

Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 33

Karolinska Institutet Partners with Johnson & Johnson Companies 34

Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 35

Janssen Pharma Enters into Partnership with Bird Rock Bio 36

DiamiR Enters into Research Agreement with Janssen Pharma 37

Janssen Pharma Enters into Agreement with University of Pennsylvania 38

Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 39

Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 40

Janssen Pharma Enters into Agreement with University of California, San Diego 41

Cypralis Enters into Research Agreement with Janssen Pharma 42

BlinkBio Enters into Discovery Agreement with Janssen Pharma 43

NeurOp Enters into Research Agreement with Janssen Pharma 44

AC Immune Enters into Research Agreement with Janssen Pharma 45

Alector Enters Into Research Agreement With Janssen Pharma 46

DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 47

Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 48

Mellitech Enters into Agreement with Janssen Pharma 50

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 51

Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 52

Janssen Pharma Enters into Licensing Agreement with Arrowhead Pharma 53

Janssen Pharma Enters into Licensing Agreement with St Vincent's Institute of Medical Research 54

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 55

Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 56

Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 57

Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 58

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 59

Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 60

Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 61

Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 62

AC Immune Enters into Licensing Agreement with Janssen Pharma 63

Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 64

Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 66

Janssen Pharma Enters into Licensing Agreement with BiocerOX 67

Orion Enters Into Licensing Agreement With Janssen Pharma 68

Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 69

GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 70

NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 71

Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 72

Shionogi Enters Into Licensing Agreement With Janssen Pharma 74

Depomed Enters Into Licensing Agreement With Janssen Pharma 75

Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 76

Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 77

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 78

VIVUS Acquires Assets from Janssen Pharma for USD135 Million 80

Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 81

Vivus Acquires Topiramate Related Patents from Janssen Pharma 83

Janssen Pharma Acquires XO1 84

Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 85

Janssen Pharmaceuticals Inc, Key Competitors 87

Janssen Pharmaceuticals Inc, Key Employees 88

Janssen Pharmaceuticals Inc, Other Locations 89

Janssen Pharmaceuticals Inc, Subsidiaries 89

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Janssen Pharmaceuticals Inc (Janssen), a subsidiary of Johnson & Johnson is a pharmaceutical company that develops drugs. The company offers medicines for an array of health conditions in therapeutic areas of attention deficit hyperactivity disorder, general medicine, mental health, neurologics, pain management, women's health, and others. It also offers treatments for acid reflux disease, infectious diseases, bipolar I disorder, schizophrenia, alzheimer's disease, epilepsy, migraine prevention and treatment. The company sells its products through a network of distributors across the US. It caters services to cardiovascular & metabolism, immunology, infectious diseases, vaccines, neuroscience,Oncology and other therapeutic areas. Janssen is headquartered in Titusville, New Jersey, the US.

Janssen Pharmaceuticals Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Janssen Pharma Acquires CERC-501 from Cerecor 17

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18

Venture Financing 19

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 19

Partnerships 20

Janssen Pharma Enters into Research and Option Agreement with Arrowhead Pharma 20

MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 21

GenomeDx Biosciences Enters into Agreement with Janssen Pharma 22

Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 23

Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 24

Janssen Pharma Enters into Research Partnership with Beacon Discovery 25

Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 26

Genomic Health Enters into Research Agreement with Janssen Pharma 27

Cerveau Technologies Enters into Agreement with Janssen Pharma 28

University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 29

PeptiDream Enters into Agreement with Janssen Pharma 30

Janssen Pharma Enters into Partnership with Premier 31

Renova Therapeutics Enters into Agreement with Janssen Pharma 32

Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 33

Karolinska Institutet Partners with Johnson & Johnson Companies 34

Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 35

Janssen Pharma Enters into Partnership with Bird Rock Bio 36

DiamiR Enters into Research Agreement with Janssen Pharma 37

Janssen Pharma Enters into Agreement with University of Pennsylvania 38

Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 39

Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 40

Janssen Pharma Enters into Agreement with University of California, San Diego 41

Cypralis Enters into Research Agreement with Janssen Pharma 42

BlinkBio Enters into Discovery Agreement with Janssen Pharma 43

NeurOp Enters into Research Agreement with Janssen Pharma 44

AC Immune Enters into Research Agreement with Janssen Pharma 45

Alector Enters Into Research Agreement With Janssen Pharma 46

DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 47

Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 48

Mellitech Enters into Agreement with Janssen Pharma 50

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 51

Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 52

Licensing Agreements 53

Janssen Pharma Enters into Licensing Agreement with Arrowhead Pharma 53

Janssen Pharma Enters into Licensing Agreement with St Vincent's Institute of Medical Research 54

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 55

Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 56

Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 57

Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 58

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 59

Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 60

Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 61

Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 62

AC Immune Enters into Licensing Agreement with Janssen Pharma 63

Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 64

Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 66

Janssen Pharma Enters into Licensing Agreement with BiocerOX 67

Orion Enters Into Licensing Agreement With Janssen Pharma 68

Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 69

GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 70

NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 71

Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 72

Shionogi Enters Into Licensing Agreement With Janssen Pharma 74

Depomed Enters Into Licensing Agreement With Janssen Pharma 75

Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 76

Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 77

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 78

Asset Transactions 80

VIVUS Acquires Assets from Janssen Pharma for USD135 Million 80

Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 81

Vivus Acquires Topiramate Related Patents from Janssen Pharma 83

Acquisition 84

Janssen Pharma Acquires XO1 84

Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 85

Janssen Pharmaceuticals Inc-Key Competitors 87

Janssen Pharmaceuticals Inc-Key Employees 88

Janssen Pharmaceuticals Inc-Locations And Subsidiaries 89

Head Office 89

Other Locations & Subsidiaries 89

Recent Developments 90

Strategy And Business Planning 90

Oct 05, 2018: Janssen signs USD 3.7bn worth licence agreements with Arrowhead 90

Legal and Regulatory 91

May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 91

Government and Public Interest 92

Feb 21, 2018: New Real-World Analysis Published in The Journal of Clinical Psychiatry Illuminates the Significant Economic Toll of Treatment-Resistant Depression on Individuals, Employers and Payers 92

Nov 30, 2017: New HIV Prevention Trials Hold Promise for New Prevention Options for Women 93

Sep 26, 2017: Janssen Announces HealtheVoices Impact Fund Recipients 94

Other Significant Developments 95

Oct 09, 2017: Johnson & Johnson investing USD 350M in EU biologics operation, adding 200 jobs 95

Appendix 96

Methodology 96

About GlobalData 96

Contact Us 96

Disclaimer 96


List Of Figure

List of Figures

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Janssen Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Janssen Pharma Acquires CERC-501 from Cerecor 17

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 19

Janssen Pharma Enters into Research and Option Agreement with Arrowhead Pharma 20

MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 21

GenomeDx Biosciences Enters into Agreement with Janssen Pharma 22

Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 23

Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 24

Janssen Pharma Enters into Research Partnership with Beacon Discovery 25

Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 26

Genomic Health Enters into Research Agreement with Janssen Pharma 27

Cerveau Technologies Enters into Agreement with Janssen Pharma 28

University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 29

PeptiDream Enters into Agreement with Janssen Pharma 30

Janssen Pharma Enters into Partnership with Premier 31

Renova Therapeutics Enters into Agreement with Janssen Pharma 32

Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 33

Karolinska Institutet Partners with Johnson & Johnson Companies 34

Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 35

Janssen Pharma Enters into Partnership with Bird Rock Bio 36

DiamiR Enters into Research Agreement with Janssen Pharma 37

Janssen Pharma Enters into Agreement with University of Pennsylvania 38

Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 39

Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 40

Janssen Pharma Enters into Agreement with University of California, San Diego 41

Cypralis Enters into Research Agreement with Janssen Pharma 42

BlinkBio Enters into Discovery Agreement with Janssen Pharma 43

NeurOp Enters into Research Agreement with Janssen Pharma 44

AC Immune Enters into Research Agreement with Janssen Pharma 45

Alector Enters Into Research Agreement With Janssen Pharma 46

DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 47

Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 48

Mellitech Enters into Agreement with Janssen Pharma 50

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 51

Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 52

Janssen Pharma Enters into Licensing Agreement with Arrowhead Pharma 53

Janssen Pharma Enters into Licensing Agreement with St Vincent's Institute of Medical Research 54

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 55

Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 56

Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 57

Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 58

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 59

Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 60

Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 61

Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 62

AC Immune Enters into Licensing Agreement with Janssen Pharma 63

Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 64

Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 66

Janssen Pharma Enters into Licensing Agreement with BiocerOX 67

Orion Enters Into Licensing Agreement With Janssen Pharma 68

Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 69

GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 70

NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 71

Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 72

Shionogi Enters Into Licensing Agreement With Janssen Pharma 74

Depomed Enters Into Licensing Agreement With Janssen Pharma 75

Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 76

Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 77

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 78

VIVUS Acquires Assets from Janssen Pharma for USD135 Million 80

Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 81

Vivus Acquires Topiramate Related Patents from Janssen Pharma 83

Janssen Pharma Acquires XO1 84

Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 85

Janssen Pharmaceuticals Inc, Key Competitors 87

Janssen Pharmaceuticals Inc, Key Employees 88

Janssen Pharmaceuticals Inc, Other Locations 89

Janssen Pharmaceuticals Inc, Subsidiaries 89

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS